Association for Molecular Pathology v. Myriad Genetics, Inc. [2013]
569 U.S. 576 · Supreme Court of the United States · United States
Quantum Computing Lawquantum-computing-lawQuantum Computing LawPatent eligibility of naturally occurring DNA sequences
Issue
Whether naturally occurring DNA segments are patent-eligible.
Held
Naturally occurring DNA is a product of nature and not patent-eligible, but synthetic cDNA is patent-eligible.
Exam use
In an exam, introduce Association for Molecular Pathology v. Myriad Genetics, Inc. with the citation only if you can remember it accurately; otherwise use the case name and court, then focus on the rule and application. A strong answer should say what Association for Molecular Pathology v. Myriad Genetics, Inc. decided, why the facts mattered, and how the authority helps resolve the new facts. Avoid treating the case as a decorative reference. Use it to prove a doctrinal step in Patent eligibility of naturally occurring DNA sequences, then move quickly to analysis.
Summary
Association for Molecular Pathology v. Myriad Genetics, Inc. is included in the Quantum Computing Law case database because it gives students a concrete authority for Patent eligibility of naturally occurring DNA sequences. The reported citation is 569 U.S. 576, and the decision is associated with Supreme Court of the United States. In revision, treat the case as a way to connect the legal issue to a real dispute rather than as an abstract rule. The key exam move is to state the holding, identify the fact pattern that made the rule matter, and then decide whether a new problem question should apply, distinguish, or limit the authority.
Facts
The material factual signal for Association for Molecular Pathology v. Myriad Genetics, Inc. is: Myriad patented isolated BRCA1 and BRCA2 genes linked to breast cancer. Students should read the linked source and turn that signal into a short fact table: parties, transaction or public-law setting, procedural posture, conduct in dispute, and the fact the court treated as decisive. This prevents vague case-dropping. In an answer on Quantum Computing Law, use the facts to explain why Patent eligibility of naturally occurring DNA sequences was live, then compare the problem facts against the facts in the case before stating any conclusion.
Procedural History
Association for Molecular Pathology v. Myriad Genetics, Inc. is reported as a decision of Supreme Court of the United States. The procedural route should be checked against the linked source before formal citation. For study notes, record whether the decision was an appeal, judicial review, trial judgment, tribunal ruling, or constitutional/application proceeding, because that posture affects how confidently the rule can be used.
Issue
Whether naturally occurring DNA segments are patent-eligible.
Held
Naturally occurring DNA is a product of nature and not patent-eligible, but synthetic cDNA is patent-eligible.
Ratio Decidendi
Naturally occurring genetic material is not patentable unless it is altered to be markedly different from its natural state.
Obiter Dicta
Check the linked source for concurring, dissenting, or obiter observations before quoting this case. If the case includes non-binding reasoning, use it as persuasive support rather than as the core rule.
Reasoning
For reasoning, start with the ratio: Naturally occurring genetic material is not patentable unless it is altered to be markedly different from its natural state. Then read the source and separate three things: the legal test, the facts used to apply that test, and any policy or institutional reason the court gave. This structure makes Association for Molecular Pathology v. Myriad Genetics, Inc. easier to use in essays and problem questions. In Quantum Computing Law, the case should be compared with related authorities on Patent eligibility of naturally occurring DNA sequences; if the jurisdiction, statute, or procedural posture differs from the exam problem, explain that limit explicitly instead of treating the authority as automatic.
Plain-English Explanation
Plainly, Association for Molecular Pathology v. Myriad Genetics, Inc. is a case to use when a Quantum Computing Law answer needs an authority on Patent eligibility of naturally occurring DNA sequences. Do not just list it. Explain the problem the court had to solve, the rule or holding it used, and the fact that made the result persuasive. That turns the case from a memorised name into evidence for your legal analysis.
Essay-Ready Explanation Generator
Version 1 of 4
Reference to Association for Molecular Pathology v. Myriad Genetics, Inc. (569 U.S. 576) strengthens a Quantum Computing Law answer because the case reflects the principle that Naturally occurring genetic material is not patentable unless it is altered to be markedly different from its natural state. Applied to a problem question, the case should be used after identifying the issue as Whether naturally occurring DNA segments are patent-eligible. The stronger essay move is to connect the material facts to the court's holding, then explain whether the present facts support the same conclusion or justify distinguishing the authority.
Underlying Concepts
quantum-computing-law
Quantum Computing Law
Patent eligibility of naturally occurring DNA sequences
case authority
exam application
Key Passages
Verify exact wording in the linked source before quoting.
Significance
Association for Molecular Pathology v. Myriad Genetics, Inc. is significant for LawConquer users because it supplies a named authority for Patent eligibility of naturally occurring DNA sequences in Quantum Computing Law. The case can anchor a paragraph, support a rule statement, or provide a contrast point when another authority points the other way. Its practical value is strongest when the student links the holding to the material facts and then explains whether the present problem is analogous or distinguishable.
Related Cases
No related cases listed.
Exam Tips
In an exam, introduce Association for Molecular Pathology v. Myriad Genetics, Inc. with the citation only if you can remember it accurately; otherwise use the case name and court, then focus on the rule and application. A strong answer should say what Association for Molecular Pathology v. Myriad Genetics, Inc. decided, why the facts mattered, and how the authority helps resolve the new facts. Avoid treating the case as a decorative reference. Use it to prove a doctrinal step in Patent eligibility of naturally occurring DNA sequences, then move quickly to analysis.
Revision Checklist
Name the issue before discussing facts so the marker sees the legal question immediately.
State the holding in one sentence, then use the ratio to explain why the court reached that result.
Use the citation and jurisdiction to show why this authority matters for the problem you are answering.
Pair this case with one supporting or contrasting authority if the question tests limits, policy, or exceptions.
Problem Question Use
Use Association for Molecular Pathology v. Myriad Genetics, Inc. in a problem question by matching the factual trigger to the new scenario. If the fact pattern aligns with Myriad patented isolated BRCA1 and BRCA2 genes linked to breast cancer., apply the ratio and explain the likely result. If a crucial fact, jurisdiction, statute, or procedural posture differs, distinguish the case and use it as a boundary rather than a controlling answer.